A5018512393- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Palliative Care and End-of-Life Issues
- Family Support in Illness
- Hematopoietic Stem Cell Transplantation
- Chemotherapy-induced organ toxicity mitigation
- Cancer survivorship and care
- Renal and related cancers
- Adolescent and Pediatric Healthcare
- Chemotherapy-induced cardiotoxicity and mitigation
- Glioma Diagnosis and Treatment
- Nutrition and Health in Aging
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Reproductive Biology and Fertility
- Testicular diseases and treatments
- Immunodeficiency and Autoimmune Disorders
- Cancer Risks and Factors
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- Ethics and Legal Issues in Pediatric Healthcare
- Reproductive Health and Technologies
- Neonatal Respiratory Health Research
Newcastle University
2016-2025
Great North Children's Hospital
2016-2025
Royal Victoria Infirmary
2013-2024
Newcastle upon Tyne Hospitals NHS Foundation Trust
2011-2024
Newcastle upon Tyne Hospital
2001-2022
National Health Service
2022
Kepler Universitätsklinikum
2021
Institute of Cancer Research
2016-2020
Princess Máxima Center
2016-2018
Royal Hospital for Sick Children
2018
Childhood and young adult cancer survivors should receive optimum care to reduce the consequences of late effects improve quality life. We can facilitate achieving this goal by international collaboration in guideline development. In 2010, International Late Effects Cancer Guideline Harmonization Group was initiated. The aim harmonization endeavor is establish a common vision integrated strategy for surveillance childhood survivors. With implementation our evidence-based methods, we provide...
We explored the feasibility of unrelated donor haematopoietic stem cell transplant (HSCT) upfront without prior immunosuppressive therapy (IST) in paediatric idiopathic severe aplastic anaemia (SAA). This cohort was then compared to matched historical controls who had undergone first-line with a sibling/family (MSD) HSCT (n = 87) or IST horse antithymocyte globulin and ciclosporin 58) second-line post-failed 24). The 2-year overall survival 96 ± 4% 91 3% MSD (P 0·30) 94 0·68) 74 9% post-IST...
With the advent of multimodality therapy, overall five-year survival rate from childhood cancer has improved considerably now exceeding 80% in developed European countries. This growing cohort survivors, with many years life ahead them, raised necessity for knowledge concerning risks adverse long-term sequelae life-saving treatments order to provide optimal screening and care identify adequate interventions. Childhood survivor cohorts Europe. Considerable advantages exist study late effects...
BackgroundCurrently, there are between 300,000 and 500,000 childhood cancer survivors (CCSs) in Europe. A significant proportion is at high risk, least 60% of them develop adverse health-related outcomes that can appear several years after treatment completion. Many unaware their personal seems to be a general lack information among healthcare providers about pathophysiology natural history treatment-related complications. This generate incorrect or delayed diagnosis treatments.MethodThe...
As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors childhood, adolescent, and young adult cancer.
Background: Long-term follow-up (LTFU) care for childhood, adolescent, and young adult (CAYA) cancer survivors is essential to preserve health quality of life (QoL).Evidence-based guidelines are needed inform optimal surveillance strategies, but many topics yet be addressed by the International Late Effects Childhood Cancer Guideline Harmonization Group (IGHG).Therefore, PanCareFollowUp Recommendations Working collaborated with stakeholders develop European harmonised recommendations in...
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with lineage switch from to myeloid leukemia, resulting in poor clinical outcomes caused by resistance chemotherapies and immunotherapies. In this study, the relapses shared oncogene breakpoints their matched lymphoid presentations originated various differentiation stages immature progenitors through committed B-cell precursors. Lineage switching is linked substantial changes...